Why the study?
Does clinical risk assessment and targeted thrombophilia screening improve management and reduce venous thromboembolism in pregnant women?
Does clinical risk assessment and targeted thrombophilia screening improve management and reduce venous thromboembolism in pregnant women?
Clinical risk assessment and targeted thrombophilia screening in early pregnancy are crucial for managing and reducing the risk of venous thromboembolism in pregnant women.
Answers are grounded in this paper and cite their sources.
Prioritizes clinical risk identification to lower pregnancy VTE; leaves open prospective validation of targeted screening.
Venous thromboembolism is an important cause of maternal morbidity and mortality. The puerperium should be regarded as the period of greatest risk. However, fatalities in early pregnancy emphasise the need to assess thrombotic risk at all stages of pregnancy. In many cases those at increased risk are potentially identifiable on clinical grounds alone such as those with a personal or family history of venous thromboembolism, obesity, or surgery. Identification of women with multiple clinical risks for thrombosis during pregnancy remains the key to reducing the incidence of this condition. In women who present with a personal or family history of proven venous thromboembolism, thrombophilia screening should be performed in early pregnancy, since the results may influence subsequent management during pregnancy. The investigation and management of patients considered at increased risk of venous thrombosis during pregnancy requires close liaison between obstetricians and haematologists familiar with this rapidly expanding and complex field of thrombophilia.
No takes yet. Share an insight, caveat, or question.
McColl et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: